Buying This 1 Biotech Stock Now Could Help Make You a Multimillionaire Retiree

Vertex Pharmaceuticals' current lineup could drive top-line growth well into the 2030s. The company should launch brand-new products that will take over after that.

The Motley Fool • 5 hours ago

Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from a Phase 4 study of JOURNAVX® (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults, that demonstrated effective pain management and enabled opioid-free recovery after a broad range of plastic surgical procedures. These data showed that the majority of patients (90.9%) in the study were opioid free through the end of treatmen.

Business Wire • Mar 5, 2026

Vertex to Participate in Upcoming March Investor Conferences

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial Officer, and Duncan McKechnie, Chief Commercial Officer, will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026, at 10:00 a.m. ET. Susie Lisa, Senior Vice President, Investor Relations, and Miroslava Minkova, Executive Director, Investor Relation.

Business Wire • Mar 5, 2026

2 Biotech Giants to Buy in 2026

These companies will offer you the fantastic combination of growth and safety. They're both trading at reasonable prices right now.

The Motley Fool • Mar 5, 2026

Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of

CRISPR Therapeutics' gene-editing platform looks fairly promising, but plenty of challenges could sink the stock. Vertex Pharmaceuticals has a robust underlying business along with some exposure to the gene editing field.

The Motley Fool • Mar 4, 2026

Vertex Pharmaceuticals Incorporated (VRTX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Vertex Pharmaceuticals Incorporated (VRTX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Seeking Alpha • Mar 3, 2026

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Investment Research • Mar 2, 2026

10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)

The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.7% yield and -10% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.

Seeking Alpha • Feb 28, 2026

Forget Centessa Pharmaceuticals: This Rare‑Disease Specialist Has a Superior Portfolio and Pipeline

Centessa Pharmaceuticals has a promising candidate, but plenty of work remains before it can launch it. Vertex Pharmaceuticals has a rich lineup of approved medicines and a deep pipeline of exciting candidates.

The Motley Fool • Feb 26, 2026

2 Top Healthcare Stocks to Buy in February

CVS Health is making changes that could improve its business this year. Vertex Pharmaceuticals should see strong commercial and clinical progress in 2026.

The Motley Fool • Feb 26, 2026